- Home
- PHYS vs JAZZ Comparison
PHYS vs JAZZ Comparison
Compare PHYS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHYS
- JAZZ
- Stock Information
- Founded
- PHYS N/A
- JAZZ 2003
- Country
- PHYS
- JAZZ Ireland
- Employees
- PHYS N/A
- JAZZ N/A
- Industry
- PHYS
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- PHYS
- JAZZ Health Care
- Exchange
- PHYS NYSE
- JAZZ Nasdaq
- Market Cap
- PHYS 8.9B
- JAZZ 8.4B
- IPO Year
- PHYS N/A
- JAZZ 2007
- Fundamental
- Price
- PHYS $24.10
- JAZZ $124.15
- Analyst Decision
- PHYS
- JAZZ Strong Buy
- Analyst Count
- PHYS 0
- JAZZ 13
- Target Price
- PHYS N/A
- JAZZ $187.15
- AVG Volume (30 Days)
- PHYS N/A
- JAZZ 1.2M
- Earning Date
- PHYS N/A
- JAZZ 04-30-2025
- Dividend Yield
- PHYS N/A
- JAZZ N/A
- EPS Growth
- PHYS N/A
- JAZZ 41.75
- EPS
- PHYS N/A
- JAZZ 8.65
- Revenue
- PHYS N/A
- JAZZ $4,068,950,000.00
- Revenue This Year
- PHYS N/A
- JAZZ $7.55
- Revenue Next Year
- PHYS N/A
- JAZZ $3.52
- P/E Ratio
- PHYS N/A
- JAZZ $14.35
- Revenue Growth
- PHYS N/A
- JAZZ 6.12
- 52 Week Low
- PHYS N/A
- JAZZ $99.06
- 52 Week High
- PHYS N/A
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- PHYS 73.61
- JAZZ 35.02
- Support Level
- PHYS $23.29
- JAZZ $137.74
- Resistance Level
- PHYS $23.50
- JAZZ $142.64
- Average True Range (ATR)
- PHYS 0.18
- JAZZ 3.93
- MACD
- PHYS 0.04
- JAZZ -2.25
- Stochastic Oscillator
- PHYS 94.41
- JAZZ 16.07
About PHYS SPROTT PHYSICAL GOLD TRUST
Sprott Physical Gold Trust is a closed-end mutual fund trust. The company provides a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical gold bullion without the inconvenience associated with direct investment in physical gold bullion. The company invests mainly in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not and will not speculate about short-term changes in gold prices.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.